Losartan Potassium Tablet, Film Coated
Product Images NDC 68788-4127

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 68788-4127). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Losartan Potassium Tab Usp 50mg (Losartan 50 mg 30s)

Label for Losartan Potassium tablets USP 50 mg by Preferred Pharmaceuticals, Inc. The label includes dosage instructions in English and Spanish, storage information, and the manufacturer Macleods Pharmaceuticals Ltd. It states the product is generic for Cozaar and provides barcode and placeholder fields for lot, batch, and expiration date details.*

FDA Label Image

Fig.3 (Losartan Figure No 3)

A forest plot chart comparing the primary composite and stroke (fatal/non-fatal) event rates between Losartan potassium and Atenolol across various patient subgroups. The chart includes hazard ratios with 95% confidence intervals, event rates as percentages, and subgroup categories such as age, gender, race, isolated systolic hypertension (ISH), diabetes, and history of cardiovascular disease (CVD).*

FDA Label Image

Fig.1 (Losartan Figure1)

A line graph comparing the percentage of patients with a primary endpoint over study months for Atenolol (dotted line) and Losartan Potassium (solid line). The x-axis represents study months up to 66, and the y-axis shows the percentage up to 16%. Annotations note an adjusted risk reduction of 13% with a p-value of 0.021.*

FDA Label Image

Fig.2 (Losartan Figure2)

A line graph comparing the percentage of patients with fatal or nonfatal stroke over a study period of up to 66 months. Two groups are represented: Atenolol (dotted line) and Losartan Potassium (solid line). The graph shows a lower stroke rate for Losartan Potassium, with an adjusted risk reduction of 25%, p=0.001.*

FDA Label Image

Fig.4 (Losartan Figure4)

A Kaplan-Meier curve comparing percent of patients with events over 48 months for Losartan potassium versus placebo. The graph shows a risk reduction of 16.1% with Losartan potassium, with the y-axis representing percent of patients with events and the x-axis representing time in months.*

FDA Label Image

Str (Losartan Structure)

Chemical structure of losartan potassium, showing the molecular arrangement including the biphenyl-tetrazole group and potassium ion.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.